Status:
COMPLETED
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Lead Sponsor:
AstraZeneca
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
Cross - Sectional study requiring one visit at the investigators office for the data collection. * Target Group: Patients that suffer from Bipolar Disorder Type 1. * YMRS - HAMILTON and GAF scales ar...
Eligibility Criteria
Inclusion
- Patients that are diagnosed with Bipolar Disorder Type 1 according to diagnostic criteria DSM - IV
- Patients that have started therapy with atypical antipsychotics as monotherapy or cotherapy with mood stabilizers the last three months, but have completed 2 full months of therapy.
- Patients with anxiety disorder can be recruited in the study unless it is dominant.
Exclusion
- Patients that use antidepressant medication
- Patients who were treated with depot antipsychotic in the last quarter before their enrollment in the study.
- Patients who are addicts of toxic substances.
- Patients who suffer from other serious diseases.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT00691353
Start Date
April 1 2008
End Date
July 1 2008
Last Update
December 3 2008
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Agrinio, Greece
2
Research Site
Alexandroupoli, Greece
3
Research Site
Athens, Greece
4
Research Site
Crete, Greece